Literature DB >> 26824429

Bundled strategies against infection after liver transplantation: Lessons from multidrug-resistant Pseudomonas aeruginosa.

Asahi Sato1, Toshimi Kaido1, Taku Iida1, Shintaro Yagi1, Koichiro Hata1, Hideaki Okajima1, Shunji Takakura2, Satoshi Ichiyama2, Shinji Uemoto1.   

Abstract

Infection is a life-threatening complication after liver transplantation (LT). A recent outbreak of multidrug-resistant Pseudomonas aeruginosa triggered changes in our infection control measures. This study investigated the usefulness of our bundled interventions against postoperative infection after LT. This before-and-after analysis enrolled 130 patients who underwent living donor or deceased donor LT between January 2011 and October 2014. We initiated 3 measures after January 2013: (1) we required LT candidates to be able to walk independently; (2) we increased the hand hygiene compliance rate and contact precautions; and (3) we introduced procalcitonin (PCT) measurement for a more precise determination of empirical antimicrobial treatment. We compared factors affecting the emergence of drug-resistant microorganisms, such as the duration of antimicrobial and carbapenem therapy and hospital stay, and outcomes such as bacteremia and death from infection between before (n = 77) and after (n = 53) the LT suspension period. The utility of PCT measurement was also evaluated. Patients' backgrounds were not significantly different before and after the protocol revision. Incidence of bacteremia (44% versus 25%; P = 0.02), detection rate of multiple bacteria (18% versus 4%; P = 0.01), and deaths from infections (12% versus 2%; P =  0.04) significantly decreased after the protocol revision. Duration of antibiotic (42.3 versus 25.1 days; P =  0.002) and carbapenem administration (15.1 versus 5.2 days; P < 0.001) and the length of postoperative hospital stay (85.4 versus 63.5 days; P =  0.048) also decreased after the protocol revision. PCT mean values were significantly higher in the bacteremia group (10.10 ng/mL), compared with the uneventful group (0.65 ng/mL; P =  0.002) and rejection group (2.30 ng/mL; P =  0.02). One-year overall survival after LT significantly increased in the latter period (71% versus 94%; P =  0.001). In conclusion, the bundled interventions were useful in preventing infections and lengthening overall survival after LT.
© 2016 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26824429     DOI: 10.1002/lt.24407

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  6 in total

1.  Sarcopenia plays a crucial role in liver transplantation.

Authors:  Toshimi Kaido; Yuhei Hamaguchi; Shinji Uemoto
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

Review 2.  Pseudomonas aeruginosa bacteremia among liver transplant recipients.

Authors:  Taohua Liu; Yuezhong Zhang; Qiquan Wan
Journal:  Infect Drug Resist       Date:  2018-11-16       Impact factor: 4.003

3.  Pre-Operative Delta-MELD is an Independent Predictor of Higher Mortality following Liver Transplantation.

Authors:  George Cholankeril; Andrew A Li; Brittany B Dennis; Chiranjeevi Gadiparthi; Donghee Kim; Alice E Toll; Benedict J Maliakkal; Sanjaya K Satapathy; Satheesh Nair; Aijaz Ahmed
Journal:  Sci Rep       Date:  2019-06-05       Impact factor: 4.379

4.  Applicability of common inflammatory markers in diagnosing infections in early period after liver transplantation in intensive care setting.

Authors:  Wojciech Figiel; Michał Grąt; Grzegorz Niewiński; Waldemar Patkowski; Krzysztof Zieniewicz
Journal:  Sci Rep       Date:  2020-03-03       Impact factor: 4.379

5.  Predictors of Mortality During Initial Liver Transplant Hospitalization and Investigation of Causes of Death.

Authors:  Ni Gong; Chao Jia; He Huang; Jing Liu; XueTing Huang; Qiquan Wan
Journal:  Ann Transplant       Date:  2020-12-04       Impact factor: 1.530

Review 6.  Management of bacterial and fungal infections in end stage liver disease and liver transplantation: Current options and future directions.

Authors:  Elda Righi
Journal:  World J Gastroenterol       Date:  2018-10-14       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.